Home Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Evaluating Combination of Investigational Oral Candidates MK-5172 and Daclatasvir for Chronic Hepatitis C
 

Keywords :   


Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Evaluating Combination of Investigational Oral Candidates MK-5172 and Daclatasvir for Chronic Hepatitis C

2013-04-22 13:30:00| Merck.com - Research & Development News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK) today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of Bristol-Myers Squibbs investigational NS5A replication complex inhibitor daclatasvir and Merck's investigational NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis C virus (HCV) infection, genotype 1. Language:  English Contact HTML:  MerckMedia:Caroline Lappetito, (267) 305-7639orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: c agreement trial combination

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
02.11Subtropical Storm Patty Graphics
02.11Tropical Storm Lane Graphics
02.11Tropical Storm Lane Wind Speed Probabilities Number 5
02.11Tropical Storm Lane Forecast Advisory Number 5
02.11Tropical Storm Lane Public Advisory Number 5
02.11Summary for Tropical Storm Lane (EP3/EP132024)
02.11Subtropical Storm Patty Forecast Discussion Number 3
02.11Subtropical Storm Patty Wind Speed Probabilities Number 3
More »